Venture Investors LLC led the funding round. Investors included the Wisconsin Alumni Research Foundation, Venture Management LLC, the State of Wisconsin Investment Board and others.
Madison Vaccines will use the money to develop its therapies and complete the second phase of a clinical trial for a DNA vaccine that would be used on patients with prostate cancer that has not spread whose prostate-specific antigen, or PSA, level is rising. The vaccine would be given to men to delay the progression of prostate cancer and put off androgen deprivation therapy.
Read more at the Milwaukee Journal Sentinel.